Day 1 : Sunday, April 29
Clinical Trial Supply Boot Camp
The attendee will be able to:
- Describe at least three (3) historical events that drove the development of GMPs
- Identify at least three (3) Quality rules to ensure IMP production meets global regulatory standards
- List three (3) regulatory requirements when shipping temperature controlled IMPs
Speakers:
Introduction to Import/Export Boot Camp
The attendees will be able to:
- Understand the basics of different terminology used in import/export
- Explain the role of different agencies involved in the country and areas they regulate
- Identify different reasons why an international shipment might be on customs hold in a country
- Compare and contrast active and passive shippers and their value in successful import/export for clinical supplies
- List the government agencies utilizing Automated Commercial Environment (ACE)
- Explain how ACE will expedite clinical supply clearance and delivery
Speakers:
Exhibitor Setup
Registration/ Information/ Welcome Table Open
Speaker / Facilitator Tour of Workshop Rooms
New Member Orientation
Meet & Greet GCSG Networking Event
GCSG Speak Easy
Day 2 : Monday, April 30
Full Breakfast / Exhibitor Displays Open
Registration / Information / Welcome Table Open
Welcome & Opening Remarks
Speakers:
Keynote: The Power of Understanding People
Room Transfer / Break
BREXIT Update - Impact to Clinical Supplies (WS9)
The attendee will be able to:
- Define BREXIT.
- Identify next steps in the BREXIT process.
- Identify two (2) key ways that BREXIT will impact Clinical Trials.
Speakers:
Building Quality into your Operations (WS15)
The attendee will be able to:
- Define the factors necessary in a quality culture.
- Identify the kind of high level operations that Quality would love to see in a Clinical Supply production.
- Explain no fewer than 3 reasons why great partnerships exist between Clinical Supply Operations and the Quality units that support them.
Speakers:
Developing a Global, Decentralized Model for the Supply of Clinical Trial Material in a Demand Led Environment (WS2)
The attendee will be able to:
- List the drivers of the Decentralised Model
- Provide examples of the importance of strategic partnering in a Decentralized Model
- Give no fewer than 2 examples of IT strategy and landscape and technology enablers
- Articulate the achievements of the Decentralized Model to date
Speakers:
Direct to Patient - Working With Your Investigator Sites & Courier to Create a Successful Partnership (WS5)
The attendee will be able to:
- Describe two (2) benefits each for the clinical site, sponsor and patient of a direct to patient trial.
- Identify at least two (2) risks for sponsors conducting direct to patient trials and develop effective mitigation strategies for these risks.
- List no fewer than 3 study characteristics that influence a decision to use a direct to patient strategy and why they should be considered.
Speakers:
I will not be attending a session at this time.
Improving Communication: Getting Clinical Trial Supplies a Seat at the Table (WS6)
The attendee will be able to:
- Explain how involving the Clinical Supplies Group in protocol development can improve overall trial outcomes.
- Identify systems that increase Clinical Supply Chain transparency for Clinical Operations.
- Explain how business acumen of clinical supplies can positively influence the clinical stakeholders.
Speakers:
Medical Devices (WS17)
The attendee will be able to:
- List no fewer than two (2) Code of Federal Regulations (CFR) that cover devices for approval.
- Explain what regulators are looking for to show device GMPs are in a state of control.
- Describe how devices can be blinded in order to ensure positive statistical significance at the end of the trial.
Speakers:
Novel Approaches to Blinding (WS18)
The attendee will be able to:
- Identify no fewer than 2 novel blinding techniques for Metered Dose Inhalers.
- Identify a novel manufacturing process to aid in blinding Oral Solid Dosage forms.
- Compare and contrast novel blinding techniques for injectable clinical trial materials.
Speakers:
Regulatory Labeling and Customs Requirements for CTM in Latin American Countries (WS7)
The attendee will be able to:
- Describe three (3) situations where knowledge of regulatory requirements can positively influence clinical supply chain outcomes.
- Summarize how differences in regulatory requirements can affect shipping and distribution channels.
- Present the best way to be aware of and access changing regulations for clinical supplies used in global clinical trials.
Speakers:
Software for Clinical Supplies (WS14)
The attendee will be able to:
- Describe at least two ways technology can benefit our patients.
- Identify at least one way to show ROI for your clinical supply chain on a your technology investment.
- Compare and contrast technology solutions for clinical trials and commercial supply chains.
Speakers:
The Impact of EU Regulation 536/2014 (Clinical Trial Regulation) (WS19)
The attendee will be able to:
- Compare and contrast how the requirements for CT Supplies in EU Regulation 536/2014 differ from those in Directive 2001/20/EC.
- Identify when EU Regulation 536/2014 became effective by law and when it will become effective in practice.
- Explain no fewer than two (2) reasons the Clinical Trial Regulation is being implemented.
Speakers:
Use of Central Pharmacies for Direct to Patient in your Clinical Supply Chain (WS4)
The attendee will be able to:
- Describe two (2) benefits each for the clinical site, sponsor and patient of a direct to patient trial.
- Identify at least two (2) risks for sponsors conducting direct to patient trials and develop effective mitigation strategies for these risks.
- Identify how use of Central Pharmacies can support delivery of medication closer to the patient thus minimizing waste.
Speakers:
Working with Virtual Teams (WS8)
The attendee will be able to:
- List no fewer than 2 reasons why virtual teams lose motivation & engagement.
- Describe ways to increase and enhance communication to keep virtual teams productive.
- Compare and contrast virtual team leadership vs co-located team leadership.
Speakers:
Return to Main Hall / Break
Expanded Access: Yesterday, Today and Challenges of Tomorrow
Speakers:
Lunch / Exhibitor Displays Open
Room Transfer / Break
A Culture of Engagement in the Workplace (WS21)
The attendee will be able to:
- Discuss reasons why employees have limited engagement or are disengaged.
- Identify no fewer than 2 ways to improve employee engagement in your work stream.
- List no fewer than 3 ways to monitor and maintain employee engagement.
Speakers:
Challenges of Cell, Gene, CAR-T and the Personalized Medicine Supply Chain (WS26)
The attendee will be able to:
- Define personalized medicine.
- Describe the process of developing supply chains for personalized medicine.
- List two (2) major challenges or strategies employed for delivering a robust personalized medicine supply chain.
- Compare and contrast the logistics requirements of standard cold chain products versus cell and gene therapy products.
- List at least two (2) concerns in the handling of cell and gene therapy clinical materials.
- Describe the appropriate classification and labeling of cell and gene therapy products to ensure compliant transportation.
Speakers:
End to End Logistics (WS20)
The attendee will be able to:
- Identify at least 2 current logistics market and technology trends supporting clinical trials.
- Discuss how the attributes of your target therapy drives logistics planning, including country and site selection.
- Define the roles and responsibilities with regards to material movement for all parties within the Clinical Supply Chain.
Speakers:
I will not be attending a session at this time.
Identifying the Right IRT for Your Clinical Trial (WS25)
The attendee will be able to:
- Discuss factors necessary to set up quality specifications for your IRT study.
- Describe how early in clinical trial developments you should begin IRT discussions.
- Explain how the use of a quality technical agreement can ensure IRT system success.
Speakers:
Impact of Automated Commercial Environment (ACE) on US Imports (WS22)
The attendee will be able to:
- List the government agencies utilizing Automated Commercial Environment (ACE).
- Identify the key clinical supply chain stakeholders that need to be notified of ACE requirements.
- Explain how ACE will expedite clinical supply clearance and delivery.
Speakers:
Importer of Record (IOR) and VAT risk (WS27)
The attendee will be able to:
- Explain the characteristics and responsibilities of Importer of Record (IOR).
- Understand and describe the impact of the recent customs ruling on IOR / VAT reclamation.
- Identify the financial impact to VAT reclamation of not aligning IOR to the recent customs ruling.
Speakers:
Investigator Sponsored Trials (WS23)
The attendee will be able to:
- Explain the roles and responsibilities of the sponsor in an Investigator Sponsored Trial (IST).
- List no fewer than 2 regulatory responsibilities of the investigator in an IST.
- Identify no fewer than 2 quality requirements for ISTs.
Speakers:
Regulatory Labeling and Customs Requirements for CTM in Asia (WS37)
The attendee will be able to:
- Describe three (3) situations where knowledge of regulatory requirements can positively influence clinical supply chain outcomes.
- Summarize how differences in regulatory requirements can affect shipping and distribution channels.
- Present the best way to be aware of and access changing regulations for clinical supplies used in global clinical trials.
Speakers:
Strategies for the Handling of Ancillary Supplies (WS31)
The attendee will be able to:
- Describe stocking and replenishment models used in the industry and how they are managed.
- Describe how far in advance an ancillary supply strategy should be considered and why.
- List special considerations for ancillary supplies managed outside the United States.
Speakers:
Supply Chain Security, Is it Important? (WS24)
The attendee will be able to:
- Explain how pedigree and the Supply Chain Security Act have an impact on your clinical supply chain.
- Identify no fewer than 2 ways GDP helps to ensure clinical supply chain security.
- Describe how drug accountability, returns and destruction is important to the security of your supply chain.
Speakers:
Temperature Excursion Analysis (WS29)
The attendee will be able to:
- Define temperature excursion for an Investigational Medicinal Product (IMP).
- Identify no fewer than 2 ways to minimize risk of a temperature excursion.
- Give at least 2 examples of ways to proactively and reactively manage temperature excursions.
Speakers:
Tips and Tricks for Effective Communications (WS30)
The attendee will be able to:
- Identify no fewer than 2 strategies to use to clarify true intent in communications.
- Give an example of ways technology can be used effectively to deliver your message.
- Demonstrate ways to adjust your communication style to the situation to achieve better outcomes.
Speakers:
Return to Main Hall / Break
Panel Discussion: BREXIT
Speakers:
Getting More from Your GCSG Membership
Speakers:
Closing Remarks and Raffle Drawings
Speakers:
Evening Entertainment -GCSG Sponsored Event
GCSG Speak Easy
Day 3 : Tuesday, May 1
Full Breakfast / Exhibitor Displays Open
Registration / Information / Welcome Table Open
Opening Remarks
Speakers:
Patient Testimonial: Perspective from a Poly Juvenile Arthritis Patient
Speakers:
Room Transfer / Break
Commercial Drug Sourcing Centrally vs Locally - Which is best? (WS36)
The attendee will be able to:
- Define central and local sourcing commercial drug product.
- List no fewer than 2 factors involved in decision on sourcing.
- Compare & contrast the best situations to use central vs local sourcing.
Speakers:
Developing a Global, Decentralized Model for the Supply of Clinical Trial Material in a Demand Led Environment (WS2)
The attendee will be able to:
- List the drivers of the Decentralised Model
- Provide examples of the importance of strategic partnering in a Decentralized Model
- Give no fewer than 2 examples of IT strategy and landscape and technology enablers
- Articulate the achievements of the Decentralized Model to date
Speakers:
I will not be attending a session at this time.
Import Export for Temperature Controlled Clinical Supplies (WS32)
The attendee will be able to:
- Detail options to maintain temperature during customs hold.
- Identify no fewer than 2 reasons why temperature controlled shipments are delayed.
- Explain the documentation that needs to be in place in order to prevent delays when moving product internationally.
Speakers:
Japan Trials (WS13)
The attendee will be able to:
- Describe three (3) situations where knowledge of Japanese regulatory requirements can positively influence clinical supply chain outcomes.
- Summarize how differences in Japanese regulatory requirements can affect shipping and distribution channels.
- Present the best way to be aware of and access changing regulations for clinical supplies used in Japanese Clinical Trials.
Speakers:
Just in Time Services, a Custom Solution for Clinical Supplies (WS1)
The attendee will be able to:
- Explain JIT labeling for clinical supplies.
- List two (2) situations where using JIT labeling is a benefit to clinical studies.
- Identify the point in the supply chain where JIT labeling is executed.
Speakers:
Managing Translations (WS11)
The attendee will be able to:
- Explain the value of backward and forward translation for clinical supply labels.
- Summarize the importance of good translations for clinical labels when doing JIT labeling.
- Determine a standard timeline for translation of clinical supply labels into multiple languages.
Speakers:
Releasing JIT in an On Demand Distribution Supply Chain (WS3)
The attendee will be able to:
- Understand an on demand quality risk based system.
- Describe the best way to utilize On Demand Labeling as a viable option to speed up the clinical supply chain.
- Identify ways to mitigate quality issues in an on demand clinical supply chain.
Speakers:
Self development and Self Promotion (WS10)
The attendee will be able to:
- Develop a 1, 3 and 5 year personal development plan which will include training and reading materials.
- Identify why we are so reticent to "toot our own horns" but why it is essential for continued employment.
- List no fewer than 3 ways that you can promote your achievements to your leadership to get the recognition you deserve.
Speakers:
Successful Sponsor Vendor Partnerships (WS35)
The attendee will be able to:
- List no fewer than three (3) competencies required to establish an optimal supplier/sponsor relationship.
- Compare and contrast the differences between successful and unsuccessful supplier/sponsor relationships.
- Explain no fewer than two (2) practices that keep sponsor companies from forming a good vendor/partner relationship and describe no fewer than two (2) ways to overcome those challenges.
Speakers:
The Changing Role of the QP (WS12)
The attendee will be able to:
- Compare and contrast how the QP role may or may not be impacted based on the various BREXIT scenarios.
- Identify when the UK will have to exit the EU.
- Explain no less than two mitigations for QP release in a UK based Clinical Supply Chain.
Speakers:
Tips for running Oncology 'Basket' Studies (WS34)
The attendee will be able to:
- Define what basket studies are and how they are used in clinical trials.
- Discuss regulatory nuances specific to basket studies.
- Options for maintaining supplies for these adaptive trials.
Speakers:
Why Clinical Trial Supply Professionals Should Care About Site and Patient-Centricity (WS33)
The attendee will be able to:
- Understand the value of creating clinical supplies keeping patient centricity in mind to improve compliance and study outcomes.
- Identify no fewer than 2 ways patient centricity can positively impact clinical supply labeling.
- List no fewer than 3 ways clinical supply shippers can be adapted with patient and site centricity in mind.
Speakers:
Room Transfer / Break
Direct to Patient - Working With Your Investigator Sites & Courier to Create a Successful Partnership (WS5)
The attendee will be able to:
- Describe two (2) benefits each for the clinical site, sponsor and patient of a direct to patient trial.
- Identify at least two (2) risks for sponsors conducting direct to patient trials and develop effective mitigation strategies for these risks.
- List no fewer than 3 study characteristics that influence a decision to use a direct to patient strategy and why they should be considered.
Speakers:
End to End Clinical Supply Planning (WS38)
The attendee will be able to:
- Explain the best way to plan for the end to end clinical supply requirements during every stage of product development.
- List no fewer than 2 tools that can be used to expedite end to end clinical supply planning.
- Identify all key stakeholders that must be involved during end to end clinical supply planning.
Speakers:
End to End Logistics (WS20)
The attendee will be able to:
- Identify at least 2 current logistics market and technology trends supporting clinical trials.
- Discuss how the attributes of your target therapy drives logistics planning, including country and site selection.
- Define the roles and responsibilities with regards to material movement for all parties within the Clinical Supply Chain.
Speakers:
I will not be attending a session at this time.
Impact of Automated Commercial Environment (ACE) on US Imports (WS22)
The attendee will be able to:
- List the government agencies utilizing Automated Commercial Environment (ACE).
- Identify the key clinical supply chain stakeholders that need to be notified of ACE requirements.
- Explain how ACE will expedite clinical supply clearance and delivery.
Speakers:
Importer of Record (IOR) and VAT risk (WS27)
The attendee will be able to:
- Explain the characteristics and responsibilities of Importer of Record (IOR).
- Understand and describe the impact of the recent customs ruling on IOR / VAT reclamation.
- Identify the financial impact to VAT reclamation of not aligning IOR to the recent customs ruling.
Speakers:
Improving Communication: Getting Clinical Trial Supplies a Seat at the Table (WS6)
The attendee will be able to:
- Explain how involving the Clinical Supplies Group in protocol development can improve overall trial outcomes.
- Identify systems that increase Clinical Supply Chain transparency for Clinical Operations.
- Explain how business acumen of clinical supplies can positively influence the clinical stakeholders.
Speakers:
ISPE: Metrics for the Clinical Supply Chain (WS39)
The attendee will be able to:
- Understand the metrics found to be most useful in organizations
- Identify best practices for data gathering
- Understand the results of ongoing inter-company comparative measures
- Articulate additional metrics that would be beneficial to benchmark and why
Speakers:
Medical Devices (WS17)
The attendee will be able to:
- List no fewer than two (2) Code of Federal Regulations (CFR) that cover devices for approval.
- Explain what regulators are looking for to show device GMPs are in a state of control.
- Describe how devices can be blinded in order to ensure positive statistical significance at the end of the trial.
Speakers:
Software for Clinical Supplies (WS14)
The attendee will be able to:
- Describe at least two ways technology can benefit our patients.
- Identify at least one way to show ROI for your clinical supply chain on a your technology investment.
- Compare and contrast technology solutions for clinical trials and commercial supply chains.
Speakers:
Strategies for the Handling of Ancillary Supplies (WS31)
The attendee will be able to:
- Describe stocking and replenishment models used in the industry and how they are managed.
- Describe how far in advance an ancillary supply strategy should be considered and why.
- List special considerations for ancillary supplies managed outside the United States.
Speakers:
Supply Chain Security, Is it Important? (WS24)
The attendee will be able to:
- Explain how pedigree and the Supply Chain Security Act have an impact on your clinical supply chain.
- Identify no fewer than 2 ways GDP helps to ensure clinical supply chain security.
- Describe how drug accountability, returns and destruction is important to the security of your supply chain.
Speakers:
Use of Central Pharmacies for Direct to Patient in your Clinical Supply Chain (WS4)
The attendee will be able to:
- Describe two (2) benefits each for the clinical site, sponsor and patient of a direct to patient trial.
- Identify at least two (2) risks for sponsors conducting direct to patient trials and develop effective mitigation strategies for these risks.
- Identify how use of Central Pharmacies can support delivery of medication closer to the patient thus minimizing waste.
Speakers:
Lunch
Room Transfer / Break
A Culture of Engagement in the Workplace (WS21)
The attendee will be able to:
- Discuss reasons why employees have limited engagement or are disengaged.
- Identify no fewer than 2 ways to improve employee engagement in your work stream.
- List no fewer than 3 ways to monitor and maintain employee engagement.
Speakers:
BREXIT Update - Impact to Clinical Supplies (WS9)
The attendee will be able to:
- Define BREXIT.
- Identify next steps in the BREXIT process.
- Identify two (2) key ways that BREXIT will impact Clinical Trials.
Speakers:
Building Quality into your Operations (WS15)
The attendee will be able to:
- Define the factors necessary in a quality culture.
- Identify the kind of high level operations that Quality would love to see in a Clinical Supply production.
- Explain no fewer than 3 reasons why great partnerships exist between Clinical Supply Operations and the Quality units that support them.
Speakers:
Challenges of Cell, Gene, CAR-T and the Personalized Medicine Supply Chain (WS26)
The attendee will be able to:
- Define personalized medicine.
- Describe the process of developing supply chains for personalized medicine.
- List two (2) major challenges or strategies employed for delivering a robust personalized medicine supply chain.
- Compare and contrast the logistics requirements of standard cold chain products versus cell and gene therapy products.
- List at least two (2) concerns in the handling of cell and gene therapy clinical materials.
- Describe the appropriate classification and labeling of cell and gene therapy products to ensure compliant transportation.
Speakers:
How to Plan and Implement an Expanded Access Program (WS28)
The attendee will be able to:
- Identify 3 access considerations and be able to distinguish between considerations that are strategic verses operational.
- Know 3 regulatory requirements that influence how an Expanded Access program should be set up.
- Identify 3 aspects of a supply plan for an EA study that must be monitored for change.
Speakers:
I will not be attending a session at this time.
Identifying the Right IRT for Your Clinical Trial (WS25)
The attendee will be able to:
- Discuss factors necessary to set up quality specifications for your IRT study.
- Describe how early in clinical trial developments you should begin IRT discussions.
- Explain how the use of a quality technical agreement can ensure IRT system success.
Speakers:
Novel Approaches to Blinding (WS18)
The attendee will be able to:
- Identify no fewer than 2 novel blinding techniques for Metered Dose Inhalers.
- Identify a novel manufacturing process to aid in blinding Oral Solid Dosage forms.
- Compare and contrast novel blinding techniques for injectable clinical trial materials.
Speakers:
Regulatory Labeling and Customs Requirements for CTM in Latin American Countries (WS7)
The attendee will be able to:
- Describe three (3) situations where knowledge of regulatory requirements can positively influence clinical supply chain outcomes.
- Summarize how differences in regulatory requirements can affect shipping and distribution channels.
- Present the best way to be aware of and access changing regulations for clinical supplies used in global clinical trials.
Speakers:
Temperature Excursion Analysis (WS29)
The attendee will be able to:
- Define temperature excursion for an Investigational Medicinal Product (IMP).
- Identify no fewer than 2 ways to minimize risk of a temperature excursion.
- Give at least 2 examples of ways to proactively and reactively manage temperature excursions.
Speakers:
Tips and Tricks for Effective Communications (WS30)
The attendee will be able to:
- Identify no fewer than 2 strategies to use to clarify true intent in communications.
- Give an example of ways technology can be used effectively to deliver your message.
- Demonstrate ways to adjust your communication style to the situation to achieve better outcomes.
Speakers:
Tips for running Oncology 'Basket' Studies (WS34)
The attendee will be able to:
- Define what basket studies are and how they are used in clinical trials.
- Discuss regulatory nuances specific to basket studies.
- Options for maintaining supplies for these adaptive trials.
Speakers:
Return to Main Hall / Break
The Importance of Data Integrity in the Clinical Supply Chain
Speakers:
Closing Remarks and Raffle Drawings
Speakers:
Vendor Reception / Exhibitor Displays Open
GCSG Speak Easy
Day 4 : Wednesday, May 2
Full Breakfast / Exhibitor Displays Open
Registration / Information / Welcome Table Open
Room Transfer / Break
Exhibitor Display Breakdown
Welcome & Opening Remarks
Speakers:
Room Transfer / Break
Commercial Drug Sourcing Centrally vs Locally - Which is best? (WS36)
The attendee will be able to:
- Define central and local sourcing commercial drug product.
- List no fewer than 2 factors involved in decision on sourcing.
- Compare & contrast the best situations to use central vs local sourcing.
Speakers:
Direct to Patient - Working With Your Investigator Sites & Courier to Create a Successful Partnership (WS5)
The attendee will be able to:
- Describe two (2) benefits each for the clinical site, sponsor and patient of a direct to patient trial.
- Identify at least two (2) risks for sponsors conducting direct to patient trials and develop effective mitigation strategies for these risks.
- List no fewer than 3 study characteristics that influence a decision to use a direct to patient strategy and why they should be considered.
Speakers:
End to End Clinical Supply Planning (WS38)
The attendee will be able to:
- Explain the best way to plan for the end to end clinical supply requirements during every stage of product development.
- List no fewer than 2 tools that can be used to expedite end to end clinical supply planning.
- Identify all key stakeholders that must be involved during end to end clinical supply planning.
Speakers:
I will not be attending a session at this time.
Importer of Record (IOR) and VAT risk (WS27)
The attendee will be able to:
- Explain the characteristics and responsibilities of Importer of Record (IOR).
- Understand and describe the impact of the recent customs ruling on IOR / VAT reclamation.
- Identify the financial impact to VAT reclamation of not aligning IOR to the recent customs ruling.
Speakers:
Investigator Sponsored Trials (WS23)
The attendee will be able to:
- Explain the roles and responsibilities of the sponsor in an Investigator Sponsored Trial (IST).
- List no fewer than 2 regulatory responsibilities of the investigator in an IST.
- Identify no fewer than 2 quality requirements for ISTs.
Speakers:
Pharmacist Networking
Speakers:
Regulatory Labeling and Customs Requirements for CTM in Asia (WS37)
The attendee will be able to:
- Describe three (3) situations where knowledge of regulatory requirements can positively influence clinical supply chain outcomes.
- Summarize how differences in regulatory requirements can affect shipping and distribution channels.
- Present the best way to be aware of and access changing regulations for clinical supplies used in global clinical trials.
Speakers:
Releasing JIT in an On Demand Distribution Supply Chain (WS3)
The attendee will be able to:
- Understand an on demand quality risk based system.
- Describe the best way to utilize On Demand Labeling as a viable option to speed up the clinical supply chain.
- Identify ways to mitigate quality issues in an on demand clinical supply chain.
Speakers:
Self development and Self Promotion (WS10)
The attendee will be able to:
- Develop a 1, 3 and 5 year personal development plan which will include training and reading materials.
- Identify why we are so reticent to "toot our own horns" but why it is essential for continued employment.
- List no fewer than 3 ways that you can promote your achievements to your leadership to get the recognition you deserve.
Speakers:
The Changing Role of the QP (WS12)
The attendee will be able to:
- Compare and contrast how the QP role may or may not be impacted based on the various BREXIT scenarios.
- Identify when the UK will have to exit the EU.
- Explain no less than two mitigations for QP release in a UK based Clinical Supply Chain.
Speakers:
Tips and Tricks for Effective Communications (WS30)
The attendee will be able to:
- Identify no fewer than 2 strategies to use to clarify true intent in communications.
- Give an example of ways technology can be used effectively to deliver your message.
- Demonstrate ways to adjust your communication style to the situation to achieve better outcomes.
Speakers:
Why Clinical Trial Supply Professionals Should Care About Site and Patient-Centricity (WS33)
The attendee will be able to:
- Understand the value of creating clinical supplies keeping patient centricity in mind to improve compliance and study outcomes.
- Identify no fewer than 2 ways patient centricity can positively impact clinical supply labeling.
- List no fewer than 3 ways clinical supply shippers can be adapted with patient and site centricity in mind.
Speakers:
Working with Virtual Teams (WS8)
The attendee will be able to:
- List no fewer than 2 reasons why virtual teams lose motivation & engagement.
- Describe ways to increase and enhance communication to keep virtual teams productive.
- Compare and contrast virtual team leadership vs co-located team leadership.
Speakers:
Room Transfer / Break
Challenges of Cell, Gene, CAR-T and the Personalized Medicine Supply Chain (WS26)
The attendee will be able to:
- Define personalized medicine.
- Describe the process of developing supply chains for personalized medicine.
- List two (2) major challenges or strategies employed for delivering a robust personalized medicine supply chain.
- Compare and contrast the logistics requirements of standard cold chain products versus cell and gene therapy products.
- List at least two (2) concerns in the handling of cell and gene therapy clinical materials.
- Describe the appropriate classification and labeling of cell and gene therapy products to ensure compliant transportation.
Speakers:
Developing a Global, Decentralized Model for the Supply of Clinical Trial Material in a Demand Led Environment (WS2)
The attendee will be able to:
- List the drivers of the Decentralised Model
- Provide examples of the importance of strategic partnering in a Decentralized Model
- Give no fewer than 2 examples of IT strategy and landscape and technology enablers
- Articulate the achievements of the Decentralized Model to date
Speakers:
How to Plan and Implement an Expanded Access Program (WS28)
The attendee will be able to:
- Identify 3 access considerations and be able to distinguish between considerations that are strategic verses operational.
- Know 3 regulatory requirements that influence how an Expanded Access program should be set up.
- Identify 3 aspects of a supply plan for an EA study that must be monitored for change.
Speakers:
I will not be attending a session at this time.
Impact of Automated Commercial Environment (ACE) on US Imports (WS22)
The attendee will be able to:
- List the government agencies utilizing Automated Commercial Environment (ACE).
- Identify the key clinical supply chain stakeholders that need to be notified of ACE requirements.
- Explain how ACE will expedite clinical supply clearance and delivery.
Speakers:
Japan Trials (WS13)
The attendee will be able to:
- Describe three (3) situations where knowledge of Japanese regulatory requirements can positively influence clinical supply chain outcomes.
- Summarize how differences in Japanese regulatory requirements can affect shipping and distribution channels.
- Present the best way to be aware of and access changing regulations for clinical supplies used in Japanese Clinical Trials.
Speakers:
Managing Translations (WS11)
The attendee will be able to:
- Explain the value of backward and forward translation for clinical supply labels.
- Summarize the importance of good translations for clinical labels when doing JIT labeling.
- Determine a standard timeline for translation of clinical supply labels into multiple languages.
Speakers:
Medical Devices (WS17)
The attendee will be able to:
- List no fewer than two (2) Code of Federal Regulations (CFR) that cover devices for approval.
- Explain what regulators are looking for to show device GMPs are in a state of control.
- Describe how devices can be blinded in order to ensure positive statistical significance at the end of the trial.
Speakers:
Software for Clinical Supplies (WS14)
The attendee will be able to:
- Describe at least two ways technology can benefit our patients.
- Identify at least one way to show ROI for your clinical supply chain on a your technology investment.
- Compare and contrast technology solutions for clinical trials and commercial supply chains.
Speakers:
Successful Sponsor Vendor Partnerships (WS35)
The attendee will be able to:
- List no fewer than three (3) competencies required to establish an optimal supplier/sponsor relationship.
- Compare and contrast the differences between successful and unsuccessful supplier/sponsor relationships.
- Explain no fewer than two (2) practices that keep sponsor companies from forming a good vendor/partner relationship and describe no fewer than two (2) ways to overcome those challenges.
Speakers:
Supply Chain Security, Is it Important? (WS24)
The attendee will be able to:
- Explain how pedigree and the Supply Chain Security Act have an impact on your clinical supply chain.
- Identify no fewer than 2 ways GDP helps to ensure clinical supply chain security.
- Describe how drug accountability, returns and destruction is important to the security of your supply chain.
Speakers:
The Impact of EU Regulation 536/2014 (Clinical Trial Regulation) (WS19)
The attendee will be able to:
- Compare and contrast how the requirements for CT Supplies in EU Regulation 536/2014 differ from those in Directive 2001/20/EC.
- Identify when EU Regulation 536/2014 became effective by law and when it will become effective in practice.
- Explain no fewer than two (2) reasons the Clinical Trial Regulation is being implemented.
Speakers:
Room Transfer / Break
BREXIT Update - Impact to Clinical Supplies (WS9)
The attendee will be able to:
- Define BREXIT.
- Identify next steps in the BREXIT process.
- Identify two (2) key ways that BREXIT will impact Clinical Trials.
Speakers:
Building Quality into your Operations (WS15)
The attendee will be able to:
- Define the factors necessary in a quality culture.
- Identify the kind of high level operations that Quality would love to see in a Clinical Supply production.
- Explain no fewer than 3 reasons why great partnerships exist between Clinical Supply Operations and the Quality units that support them.
Speakers:
End to End Clinical Supply Planning (WS38)
The attendee will be able to:
- Explain the best way to plan for the end to end clinical supply requirements during every stage of product development.
- List no fewer than 2 tools that can be used to expedite end to end clinical supply planning.
- Identify all key stakeholders that must be involved during end to end clinical supply planning.
Speakers:
I will not be attending a session at this time.
Import Export for Temperature Controlled Clinical Supplies (WS32)
The attendee will be able to:
- Detail options to maintain temperature during customs hold.
- Identify no fewer than 2 reasons why temperature controlled shipments are delayed.
- Explain the documentation that needs to be in place in order to prevent delays when moving product internationally.
Speakers:
Improving Communication: Getting Clinical Trial Supplies a Seat at the Table (WS6)
The attendee will be able to:
- Explain how involving the Clinical Supplies Group in protocol development can improve overall trial outcomes.
- Identify systems that increase Clinical Supply Chain transparency for Clinical Operations.
- Explain how business acumen of clinical supplies can positively influence the clinical stakeholders.
Speakers:
ISPE: Metrics for the Clinical Supply Chain (WS39)
The attendee will be able to:
- Understand the metrics found to be most useful in organizations
- Identify best practices for data gathering
- Understand the results of ongoing inter-company comparative measures
- Articulate additional metrics that would be beneficial to benchmark and why
Speakers:
Just in Time Services, a Custom Solution for Clinical Supplies (WS1)
The attendee will be able to:
- Explain JIT labeling for clinical supplies.
- List two (2) situations where using JIT labeling is a benefit to clinical studies.
- Identify the point in the supply chain where JIT labeling is executed.
Speakers:
Regulatory Labeling and Customs Requirements for CTM in Latin American Countries (WS7)
The attendee will be able to:
- Describe three (3) situations where knowledge of regulatory requirements can positively influence clinical supply chain outcomes.
- Summarize how differences in regulatory requirements can affect shipping and distribution channels.
- Present the best way to be aware of and access changing regulations for clinical supplies used in global clinical trials.
Strategies for the Handling of Ancillary Supplies (WS31)
The attendee will be able to:
- Describe stocking and replenishment models used in the industry and how they are managed.
- Describe how far in advance an ancillary supply strategy should be considered and why.
- List special considerations for ancillary supplies managed outside the United States.
Speakers:
Temperature Excursion Analysis (WS29)
The attendee will be able to:
- Define temperature excursion for an Investigational Medicinal Product (IMP).
- Identify no fewer than 2 ways to minimize risk of a temperature excursion.
- Give at least 2 examples of ways to proactively and reactively manage temperature excursions.
Speakers:
Tips for running Oncology 'Basket' Studies (WS34)
The attendee will be able to:
- Define what basket studies are and how they are used in clinical trials.
- Discuss regulatory nuances specific to basket studies.
- Options for maintaining supplies for these adaptive trials.
Speakers:
Use of Central Pharmacies for Direct to Patient in your Clinical Supply Chain (WS4)
The attendee will be able to:
- Describe two (2) benefits each for the clinical site, sponsor and patient of a direct to patient trial.
- Identify at least two (2) risks for sponsors conducting direct to patient trials and develop effective mitigation strategies for these risks.
- Identify how use of Central Pharmacies can support delivery of medication closer to the patient thus minimizing waste.
Speakers:
Lunch
Room Transfer / Break
E-labeling: A Demonstration
Speakers:
Closing Remarks and Raffle Drawings
Speakers: